MCID: ALL014
MIFTS: 40

Allergic Encephalomyelitis

Categories: Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Allergic Encephalomyelitis

MalaCards integrated aliases for Allergic Encephalomyelitis:

Name: Allergic Encephalomyelitis 53
Experimental Autoimmune Encephalomyelitis 72

Classifications:



External Ids:

UMLS 72 C0014072

Summaries for Allergic Encephalomyelitis

MalaCards based summary : Allergic Encephalomyelitis, also known as experimental autoimmune encephalomyelitis, is related to myelitis and acute disseminated encephalomyelitis. An important gene associated with Allergic Encephalomyelitis is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions and TNF signaling pathway. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and spinal cord, and related phenotypes are hematopoietic system and immune system

Wikipedia : 75 Experimental autoimmune encephalomyelitis, sometimes experimental allergic encephalomyelitis (EAE) is an... more...

Related Diseases for Allergic Encephalomyelitis

Diseases related to Allergic Encephalomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 myelitis 30.6 MOG MBP
2 acute disseminated encephalomyelitis 30.3 MOG MBP
3 optic neuritis 30.2 PLP1 MOG MBP
4 spinal cord disease 30.1 MOG MBP
5 neuromyelitis optica 30.1 MOG MBP
6 nervous system disease 29.9 MOG MBP CCL2
7 proteasome-associated autoinflammatory syndrome 1 29.7 CCL5 CCL2
8 encephalitis 29.5 MOG CCL5 CCL2
9 central nervous system disease 29.3 PLP1 MOG MBP CCL2
10 relapsing-remitting multiple sclerosis 29.2 MOG MBP CCL5
11 neuritis 29.2 MOG MBP CCL5 CCL2
12 demyelinating disease 29.1 PLP1 MOG MBP CCL5 CCL2
13 multiple sclerosis 28.0 PLP1 MOG MBP CD86 CCL5 CCL2
14 autoimmune disease of central nervous system 27.5 PLP1 MOG MBP CCL5 CCL2
15 autoimmune disease 11.0
16 pertussis 10.7
17 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.6
18 allergic hypersensitivity disease 10.6
19 cytokine deficiency 10.5
20 encephalopathy 10.4
21 ataxia and polyneuropathy, adult-onset 10.3
22 paraplegia 10.3
23 vaccinia 10.3
24 orchitis 10.3
25 vasculitis 10.3
26 leukodystrophy, hypomyelinating, 2 10.3 PLP1 MBP
27 balo concentric sclerosis 10.2 MOG MBP
28 panencephalitis, subacute sclerosing 10.2 MOG MBP
29 internuclear ophthalmoplegia 10.2 MOG MBP
30 pelizaeus-merzbacher disease 10.2 PLP1 MBP
31 autoimmune disease of peripheral nervous system 10.2 MOG MBP
32 autoimmune optic neuritis 10.2 MOG MBP
33 uveitis 10.2
34 lymphopenia 10.2
35 measles 10.2
36 cranial nerve disease 10.2 MOG MBP
37 rabies 10.1
38 gout 10.1
39 thyroiditis 10.1
40 48,xyyy 10.1
41 anterior uveitis 10.1
42 tremor 10.1
43 optic nerve disease 10.1 MOG MBP
44 secondary progressive multiple sclerosis 10.0 MBP CCL2
45 hashimoto thyroiditis 10.0
46 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
47 hydrops, lactic acidosis, and sideroblastic anemia 10.0
48 tetanus 10.0
49 retinal vasculitis 10.0
50 neutropenia 10.0

Graphical network of the top 20 diseases related to Allergic Encephalomyelitis:



Diseases related to Allergic Encephalomyelitis

Symptoms & Phenotypes for Allergic Encephalomyelitis

MGI Mouse Phenotypes related to Allergic Encephalomyelitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.35 CCL5 CD86 MBP MOG PLP1
2 immune system MP:0005387 9.1 CCL2 CCL5 CD86 MBP MOG PLP1

Drugs & Therapeutics for Allergic Encephalomyelitis

Drugs for Allergic Encephalomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 2 106266-06-2 5073
3
Selenium Approved, Investigational, Vet_approved Phase 1, Phase 2 7782-49-2
4
Tocopherol Approved, Investigational Phase 1, Phase 2 1406-66-2, 54-28-4 14986
5
Lamotrigine Approved, Investigational Phase 2 84057-84-1 3878
6
Atorvastatin Approved Phase 2 134523-00-5 60823
7
Interferon beta-1b Approved Phase 2 145155-23-3
8
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
9
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
10
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
11
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
13
Simvastatin Approved Phase 2 79902-63-9 54454
14
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
15
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
16
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
17
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-02-9 14985
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
19 Tocotrienol Investigational Phase 1, Phase 2 6829-55-6
20
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
21 Dopamine Agents Phase 2
22 Serotonin Antagonists Phase 2
23 Serotonin Agents Phase 2
24 Dopamine Antagonists Phase 2
25 Micronutrients Phase 1, Phase 2
26 Trace Elements Phase 1, Phase 2
27 Vitamins Phase 1, Phase 2
28 Nutrients Phase 1, Phase 2
29 Calcium, Dietary Phase 2
30 Antioxidants Phase 1, Phase 2
31 Ginkgo Phase 1, Phase 2
32 Alpha-lipoic Acid Phase 1, Phase 2
33 Tocotrienols Phase 1, Phase 2
34 Vitamin B9 Phase 1, Phase 2
35 Tocopherols Phase 1, Phase 2
36 Vitamin B Complex Phase 1, Phase 2
37 Folate Phase 1, Phase 2
38 Thioctic Acid Phase 1, Phase 2
39 Sodium Channel Blockers Phase 2
40 Psychotropic Drugs Phase 2
41 Central Nervous System Depressants Phase 2
42 Tranquilizing Agents Phase 2
43 Diuretics, Potassium Sparing Phase 2
44 Anticonvulsants Phase 2
45 Antipsychotic Agents Phase 2
46 calcium channel blockers Phase 2
47 Hormones Phase 1, Phase 2
48 Protective Agents Phase 1, Phase 2
49 Neurotransmitter Agents Phase 1, Phase 2
50 Anti-Inflammatory Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study Unknown status NCT02976688 Phase 2, Phase 3
2 The Effect of MS14 in Association With Risperidone in Treatment of Schizophrenia: A Double Blind Randomized Control Trial Unknown status NCT01083381 Phase 2 MS14;Risperidone
3 Natural Antioxidants in the Treatment of Multiple Sclerosis Completed NCT00010842 Phase 1, Phase 2 Ginkgo biloba;Alpha-lipoic acid;Vitamin E/Selenium;Essential fatty acids
4 Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis Completed NCT01377870 Phase 1, Phase 2
5 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial Completed NCT00257855 Phase 2 Lamotrigine
6 Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis Completed NCT00248378 Phase 1, Phase 2 Smoked Cannabis
7 Explorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS) Completed NCT00781872 Phase 1, Phase 2
8 SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study ("SWABIMS Follow Up-study") Completed NCT01111656 Phase 2 Interferon beta-1b group;Interferon beta-1b/Atorvastatin group
9 Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis. Completed NCT00942591 Phase 2 Interferon beta 1b;Atorvastatin
10 Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse Recruiting NCT03752307 Phase 1, Phase 2 Isoxsuprine Hydrochloride;Placebo;Corticosteroid
11 A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage Not yet recruiting NCT03896217 Phase 2 Simvastatin
12 A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis Terminated NCT01134627 Phase 2 Minocycline;Placebo
13 Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis Withdrawn NCT00939549 Phase 2 Cyclophosphamide/Glatiramer acetate
14 An Open-label, Randomised, Crossover Study to Assess the Relative Bioavailability of Different 2mg Formulations of GSK2018682(S1P1 Agonist) in Healthy Volunteers Completed NCT01466322 Phase 1 GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
15 to Investigate the Maternal Serum IL-17 Levels in Pregnant Women With Intrahepatic Cholestasis of Pregnancy Unknown status NCT01898832
16 Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients Unknown status NCT02489877
17 Isfahan University of Medical Sciences Completed NCT02696590
18 A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis Completed NCT02647502
19 The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis Recruiting NCT02050646
20 The Role of IL-II in the Development of Autoimmune Response in Multiple Sclerosis Recruiting NCT03735823
21 The Effect of the Ketogenic Diet on Patients With Relapsing Remitting Multiple Sclerosis Recruiting NCT03718247
22 The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With Clinically Isolated Syndrome Measured by Dynamic Contrast Enhanced Magnetic Resonance Imaging Recruiting NCT03451955
23 Evaluation of the Influence of Salt Intake on TH17 Interleukin(IL)-17 Producing CD4+ Helper T Cells in Human Subjects Active, not recruiting NCT02261688
24 Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome Not yet recruiting NCT03841318
25 Calorie Restriction as a Novel Therapeutic Tool to Manipulate Immunity and Improve Therapeutic Potential of First Line Drug Treatments During Relapsing Remitting Multiple Sclerosis Not yet recruiting NCT04042415
26 Clinical Relevance of miR-142-3p as Potential Biomarker of Synaptopathy in Multiple Sclerosis Not yet recruiting NCT03999788

Search NIH Clinical Center for Allergic Encephalomyelitis

Genetic Tests for Allergic Encephalomyelitis

Anatomical Context for Allergic Encephalomyelitis

MalaCards organs/tissues related to Allergic Encephalomyelitis:

41
T Cells, Brain, Spinal Cord, B Cells, Bone, Endothelial, Monocytes

Publications for Allergic Encephalomyelitis

Articles related to Allergic Encephalomyelitis:

(show top 50) (show all 10989)
# Title Authors PMID Year
1
The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis. 38
31290453 2019
2
Altered expression patterns of complement factor H and miR-146a genes in acute-chronic phases in experimental autoimmune encephalomyelitis mouse. 38
30972735 2019
3
Gut microbiota depletion from early adolescence alters adult immunological and neurobehavioral responses in a mouse model of multiple sclerosis. 38
31247271 2019
4
Neuroprotective natural products against experimental autoimmune encephalomyelitis: A review. 38
31376428 2019
5
The adenosine A2A receptor antagonist SCH58261 reduces macrophage/microglia activation and protects against experimental autoimmune encephalomyelitis in mice. 38
31226280 2019
6
Microglia suppress the secondary progression of autoimmune encephalomyelitis. 38
31106910 2019
7
The modulatory effects of luteolin on cyclic AMP/Ciliary neurotrophic factor signaling pathway in experimentally induced autoimmune encephalomyelitis. 38
31185137 2019
8
Cathepsin E in neutrophils contributes to the generation of neuropathic pain in experimental autoimmune encephalomyelitis. 38
31095099 2019
9
Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. 38
31030237 2019
10
IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. 38
31341075 2019
11
EAE-induced upregulation of mitochondrial MnSOD is associated with increases of mitochondrial SGK1 and Tom20 protein in the mouse kidney cortex. 38
31177508 2019
12
Experimental Autoimmune Encephalomyelitis Potentiates Mouse Mast Cell Protease 4-Dependent Pressor Responses to Centrally or Systemically Administered Big Endothelin-1. 38
31248979 2019
13
Gold nanoparticles and polyethylene glycol alleviate clinical symptoms and alter cytokine secretion in a mouse model of experimental autoimmune encephalomyelitis. 38
30957389 2019
14
Copper chelation and autoimmunity differentially impact myelin in the hippocampal-prefrontal circuit. 38
31254928 2019
15
Experimental autoimmune encephalomyelitis accelerates remyelination after lysophosphatidylcholine-induced demyelination in the corpus callosum. 38
31228686 2019
16
2-Carba cyclic phosphatidic acid inhibits lipopolysaccharide-induced prostaglandin E2 production in a human macrophage cell line. 38
31367683 2019
17
Synchrotron radiation microtomography of brain hemisphere and spinal cord of a mouse model of multiple sclerosis revealed a correlation between capillary dilation and clinical score. 38
30291810 2019
18
Dexras1 Deletion and Iron Chelation Promote Neuroprotection in Experimental Optic Neuritis. 38
31406150 2019
19
Matrine protects oligodendrocytes by inhibiting their apoptosis and enhancing mitochondrial autophagy. 38
31404585 2019
20
Prevention and treatment of experimental autoimmune encephalomyelitis induced mice with 1, 25-dihydroxyvitamin D3. 38
31402771 2019
21
Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α. 38
31209101 2019
22
Astrocytes in multiple sclerosis and experimental autoimmune encephalomyelitis: Star-shaped cells illuminating the darkness of CNS autoimmunity. 38
31125711 2019
23
The Alzheimer's Disease-Associated Protein BACE1 Modulates T Cell Activation and Th17 Function. 38
31209103 2019
24
Helminths products directly modulate T cells that mediate experimental autoimmune encephalomyelitis. 38
31016721 2019
25
The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity. 38
31403472 2019
26
Down-regulation of taurine-up-regulated gene 1 attenuates inflammation by sponging miR-9-5p via targeting NF-κB1/p50 in multiple sclerosis. 38
31394128 2019
27
Low-Dose Subcutaneous Anti-CD20 Treatment Depletes Disease Relevant B Cell Subsets and Attenuates Neuroinflammation. 38
31435856 2019
28
Nitration of Drp1 provokes mitophagy activation mediating neuronal injury in experimental autoimmune encephalomyelitis. 38
31377418 2019
29
MiR-125a-5p Regulates Vitamin D Receptor Expression in a Mouse Model of Experimental Autoimmune Encephalomyelitis. 38
31428926 2019
30
The therapeutic effect of platelet-rich plasma on the experimental autoimmune encephalomyelitis mice. 38
31103935 2019
31
Opposing T cell responses in experimental autoimmune encephalomyelitis. 38
31391585 2019
32
MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis. 38
31412103 2019
33
Curcumin ameliorates experimental autoimmune encephalomyelitis in a C57BL/6 mouse model. 38
31033006 2019
34
Continuous cuprizone intoxication allows active experimental autoimmune encephalomyelitis induction in C57BL/6 mice. 38
31016368 2019
35
Sirtuin-1 in immunotherapy: A Janus-headed target. 38
30605226 2019
36
Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model. 38
31402611 2019
37
SLAMF9 regulates pDC homeostasis and function in health and disease. 38
31346085 2019
38
Therapeutic treatment with Modafinil decreases the severity of experimental autoimmune encephalomyelitis in mice. 38
31425975 2019
39
Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA. 38
31416452 2019
40
Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis. 38
31417666 2019
41
Therapeutic impact of orally administered cannabinoid oil extracts in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis. 38
31213295 2019
42
Interleukin-1 receptor associated kinase (IRAK)-M -mediated type 2 microglia polarization ameliorates the severity of experimental autoimmune encephalomyelitis (EAE). 38
31036429 2019
43
NLRC3 expression in dendritic cells attenuates CD4+ T cell response and autoimmunity. 38
31290162 2019
44
X-tra X: An escape to autoimmunity. 38
31403466 2019
45
Exercise intensity-dependent immunomodulatory effects on encephalomyelitis. 38
31368247 2019
46
Sulfatide-activated type II NKT cells suppress immunogenic maturation of lung dendritic cells in murine models of asthma. 38
31432714 2019
47
Dynamic Mitochondrial Migratory Features Associated with Calcium Responses during T Cell Antigen Recognition. 38
31201236 2019
48
Dendritic Cell Accumulation in the Gut and Central Nervous System Is Differentially Dependent on α4 Integrins. 38
31399516 2019
49
A TLR-CXCL1 pathway in DRG neurons induces neutrophil accumulation in the DRG and mechanical allodynia in EAE mice. 38
31427756 2019
50
Periodontal Ligament Stem Cells: Current Knowledge and Future Perspectives. 38
31017047 2019

Variations for Allergic Encephalomyelitis

Expression for Allergic Encephalomyelitis

Search GEO for disease gene expression data for Allergic Encephalomyelitis.

Pathways for Allergic Encephalomyelitis

GO Terms for Allergic Encephalomyelitis

Biological processes related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.71 PLP1 CCL5 CCL2
2 cytokine-mediated signaling pathway GO:0019221 9.63 CD86 CCL5 CCL2
3 cellular response to interferon-gamma GO:0071346 9.61 CCL5 CCL2
4 response to toxic substance GO:0009636 9.61 MBP CCL5
5 viral entry into host cell GO:0046718 9.6 MOG CD86
6 cell chemotaxis GO:0060326 9.59 CCL5 CCL2
7 neutrophil chemotaxis GO:0030593 9.58 CCL5 CCL2
8 cellular response to interleukin-1 GO:0071347 9.58 CCL5 CCL2
9 chemokine-mediated signaling pathway GO:0070098 9.57 CCL5 CCL2
10 cellular response to organic cyclic compound GO:0071407 9.56 CCL5 CCL2
11 positive regulation of T cell proliferation GO:0042102 9.55 CD86 CCL5
12 myelination GO:0042552 9.52 PLP1 MBP
13 substantia nigra development GO:0021762 9.51 PLP1 MBP
14 MAPK cascade GO:0000165 9.5 MBP CCL5 CCL2
15 monocyte chemotaxis GO:0002548 9.49 CCL5 CCL2
16 protein kinase B signaling GO:0043491 9.48 CCL5 CCL2
17 lymphocyte chemotaxis GO:0048247 9.43 CCL5 CCL2
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.4 CCL5 CCL2
19 cellular response to fibroblast growth factor stimulus GO:0044344 9.37 CCL5 CCL2
20 eosinophil chemotaxis GO:0048245 9.26 CCL5 CCL2
21 immune response GO:0006955 9.26 MBP CD86 CCL5 CCL2
22 macrophage chemotaxis GO:0048246 9.16 CCL5 CCL2
23 axon ensheathment GO:0008366 8.62 PLP1 MBP

Molecular functions related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.26 MOG CD86
2 chemokine activity GO:0008009 9.16 CCL5 CCL2
3 CCR chemokine receptor binding GO:0048020 8.96 CCL5 CCL2
4 structural constituent of myelin sheath GO:0019911 8.62 PLP1 MBP

Sources for Allergic Encephalomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....